About APOSAN
APOSAN is a Healthcare company. APOSAN is focused on Parkinsons disease treatment solutions. It operates on a Direct-to-Consumer (D2C) model. The company has 656 employees. Its Indian entity Rusan Pharma Limited reported revenue of ₹392 Cr. APOSAN offers products and services including APOSAN ®. Its focus areas include Pharmaceuticals and Neurological Treatments.
Company details
APOSAN, managed by Rusan Pharma Ltd., is dedicated to providing treatment for Parkinsons disease through its primary product, APOSAN , an Apomorphine injection. It is used for managing motor fluctuations in patients with Parkinsons disease not sufficiently controlled by oral medications. The company operates in the healthcare sector, specifically targeting neurological disorders with innovative pharmaceutical solutions. Support services like the APOSAN Hope Program and nurse coordination are also provided to assist patients and caregivers in India.
- Employees 656
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Social Facebook YouTube
- Legal Name Rusan Pharma Ltd.
- Date of Incorporation 15 Mar, 1994
- Jurisdiction Mumbai, Maharashtra, India
- Annual Revenue₹392 Cr
FY 2025 · +9% YoY
- Net Profit₹48.84 Cr
FY 2025 · 12% margin
- EBITDA₹89.66 Cr
FY 2025 · 23% margin
- Employee Count656
Associated legal entities of APOSAN
APOSAN operates through Rusan Pharma Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Rusan Pharma Limited CIN U24230MH1994PLC077069 | Active | 15 Mar 1994 | Mumbai, Maharashtra | ₹392 Cr | 656 | 5 | View details |
Products & Services of APOSAN
APOSAN offers a comprehensive portfolio of products and services, including APOSAN ®.
Apomorphine injection for managing Parkinson’s disease symptoms.
Apps and channels of APOSAN
its YouTube channel Aposan India has 6 subscribers.
Board of directors of Rusan Pharma Limited (APOSAN)
Rusan Pharma Limited is the primary company behind APOSAN. The board of Rusan Pharma Limited currently have 5 directors; the longest-serving is Navin Satyapal Sexena, appointed in 1994. 8 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Navin Satyapal Sexena DIN 00109583 | Director | 15 Mar 1994 | 32 yrs 7 mo | Rusan Pharma Limited |
| Kunal Navin Saxena DIN 05267911 | Managing Director | 05 Apr 2012 | 14 yrs 6 mo | Rusan Pharma Limited |
| Balasaheb Annasaheb Patil DIN 00143017 | Whole-time director | 17 Oct 2012 | 14 yrs | Rusan Pharma Limited |
| Aakarsh Navin Saxena DIN 07432845 | Whole-time director | 10 Feb 2016 | 10 yrs 8 mo | Rusan Pharma Limited |
| Sandeep Verma DIN 07212506 | Director | 20 Mar 2023 | 3 yrs 7 mo | Rusan Pharma Limited |
Financials of APOSAN
Figures of Rusan Pharma Limited, the primary company behind APOSAN, for FY 2025. Revenue was ₹392 Cr (+9% year on year). Net profit was ₹48.84 Cr (12% margin). EBITDA was ₹89.66 Cr (23% margin). Revenue has grown at a compounded annual rate of +9% over three years and +12% over five years.
- ₹392 CrRevenue · FY 2025 · +9% YoY
- ₹48.84 CrNet profit · 12% margin
- ₹89.66 CrEBITDA · 23% margin
- ₹4.84 CrPaid-up capital
- 656Employees (provident fund records)
- +9%Revenue CAGR, 3 years
- +12%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Rusan Pharma Limited are on its company page.
Detailed financial statements for APOSAN
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Top companies in Neurology
10 companies that operate in the same segment as APOSAN (Neurology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided. | 1999 | Tirat Carmel, Haifa District, Israel | USD 574.2 M | – | 541 | |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers | 2019 | San Francisco, California, United States | USD 144.72 M | – | 76 | |
Small molecule drugs for rare diseases are developed. | 1998 | South Plainfield, New Jersey, United States | USD 248.1 M | USD 1.73 B | 939 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Aposan
Complete news archive for APOSAN
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about APOSAN
APOSAN has 656 employees.
The primary company behind APOSAN, Rusan Pharma Limited, reported revenue of ₹392 Cr for FY 2025, up 9% year on year.
APOSAN, managed by Rusan Pharma Ltd., is dedicated to providing treatment for Parkinsons disease through its primary product, APOSAN , an Apomorphine injection. It is used for managing motor fluctuations in patients with Parkinsons disease not sufficiently controlled by oral medications. The company operates in the healthcare sector, specifically targeting neurological disorders with innovative pharmaceutical solutions. Support services like the APOSAN Hope Program and nurse coordination are also provided to assist patients and caregivers in India.
APOSAN offers APOSAN ®.
APOSAN operates through Rusan Pharma Limited.
The legal entities of APOSAN currently have 5 directors, including Kunal Navin Saxena, Balasaheb Annasaheb Patil, Sandeep Verma and others.